Los Angeles, USA, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Kinase Inhibitor Pipeline Analysis: Key Pharma Companies, and Emerging Therapies Offering New Horizons in Cancer Care
Several pharmaceutical companies are developing the Checkpoint Kinase Inhibitors as one of the most promising therapies owing to the treatment of Cancer and Advanced solid tumors.
DelveInsight’s ‘Checkpoint Kinase Inhibitor Pipeline Insights’ report lays out a complete view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development, and growth prospects across the Checkpoint Kinase Inhibitor landscape.
Some of the key highlights of the Checkpoint Kinase Inhibitor Pipeline report:
Got queries? Want to know more? Request for Sample @ Checkpoint Kinase Inhibitor Emerging Therapies and Forecast
Checkpoint Kinases
The development of Checkpoint Kinase Inhibitors to treat cancer has been a major objective in drug discovery. Checkpoint Kinases are protein kinases, Chk1 and Chk2, Ser/Thr protein kinases, which function as key regulatory kinases in cellular DNA damage response pathways limiting cell-cycle progression in the presence of DNA damage.
Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies.
For more information on Checkpoint Kinase Inhibitors, visit Checkpoint Kinase Inhibitor Pipeline Analysis
Checkpoint Kinase Inhibitor Pipeline Drugs
Request for Sample to know more @ Checkpoint Kinase Inhibitor Pipeline Analysis, Key Companies and Futuristic Trends
Checkpoint Kinase Inhibitor Therapeutic Assessment
The Checkpoint Kinase Inhibitor Pipeline report proffers exhaustive insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs.
By Product Type
By Stage
By Molecule Type
By Route of Administration
By Stage and Route of AdministrationBy Stage and Product Type
Get in touch with our Business executive for Drug Pipeline Assessment and Consulting Solutions
Scope of the Report
Coverage: GlobalKey Players: Boehringer Ingelheim, CanBas, Vernalis, Sierra Oncology, Pharos I&BT Co, Eli Lilly and company, Sentinel Oncology, IMPACT Therapeutics, Pink Biopharma.Key Checkpoint Kinase Inhibitor Pipeline Therapies: BI 765063, CBP501, VER-250840, SRA737, PHI-101, Prexasertib, SOL 578, IMP10, and Research Programme: checkpoint kinase inhibitors.
Reach out @ Checkpoint Kinase Inhibitor Pipeline: Novel therapies and Emerging Technologies
Key Questions Answered in the Report
Request for Webex demo of the report @ Checkpoint Kinase Inhibitor Pipeline Analysis and Emerging Trends
Table of Contents
Visit to know more of what’s covered @ Checkpoint Kinase Inhibitor Emerging Therapies
Related Reports
Global Kinase Inhibitor In Autoimmune Diseases MarketDelveInsight’s ‘Global Kinase Inhibitor in Autoimmune Diseases – Market Insights and Market Forecast – 2030’ report.
Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer MarketDelveInsight’s ‘Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast-2030’ report.
Cyclin-Dependent Kinase Like 5 Cdkl5 Deficiency Disorder MarketDelveInsight's "Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder - Market Insights, Epidemiology, and Market Forecast-2030" report.
Pyruvate Kinase Deficiency MarketDelveInsight's "Pyruvate Kinase Deficiency - Market Insights, Epidemiology, and Market Forecast-2030" report.
Bruton’s Tyrosine Kinase Btk Inhibitors Competitive Landscape Pipeline And Market AnalysisDelveInsight’s “Bruton's Tyrosine Kinase (BTK) Inhibitors – Competitive Landscape, Market and Pipeline Analysis, 2020” report.
Anaplastic Lymphoma Kinase Inhibitor Pipeline InsightDelveInsight’s "Anaplastic Lymphoma Kinase (ALK) Inhibitor - Pipeline Insights, 2021" report.
Thymidine Kinase 2 Deficiency Pipeline InsightDelveInsight’s "Thymidine Kinase 2 Deficiency (TK2D) Pipeline Insights, 2021" report.
AXL Kinase Inhibitor Pipeline InsightDelveInsight’s, “AXL Kinase Inhibitor - Pipeline Insight, 2021” report.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
